Pharmaceutical formulations of bictegravir and lenacapavir
AssigneeGilead Sciences, Inc.
InventorsPriyanka Arora, Julie A. Fogarty, Marina A. Clampffer
Life of this patent
Estimating the term…
Abstract
The disclosure provides a solid oral dosage form comprising bictegravir or a pharmaceutically acceptable salt thereof, and lenacapavir or a pharmaceutically acceptable salt thereof.
Claims41
1-18. (canceled)
A tablet comprising bictegravir or a pharmaceutically acceptable salt thereof and lenacapavir or a pharmaceutically acceptable salt thereof, wherein the amount of bictegravir or pharmaceutically acceptable salt thereof corresponds to about 75 mg bictegravir free acid, and wherein the amount of lenacapavir or pharmaceutically acceptable salt thereof corresponds to about 50 mg lenacapavir free acid.
(canceled)
(canceled)
23-25. (canceled)
31-40. (canceled)
44-46. (canceled)
50-56. (canceled)
58-65. (canceled)
(canceled)
(canceled)
72-79. (canceled)
A tablet comprising bictegravir or a pharmaceutically acceptable salt thereof and lenacapavir or a pharmaceutically acceptable salt thereof, wherein the amount of bictegravir or pharmaceutically acceptable salt thereof corresponds to about 75 mg bictegravir free acid, and wherein the amount of lenacapavir or pharmaceutically acceptable salt thereof corresponds to about 50 mg lenacapavir free acid wherein
- the bictegravir or pharmaceutically acceptable salt thereof is bictegravir sodium and the lenacapavir or pharmaceutically acceptable salt thereof is lenacapavir sodium;
- and wherein
- the tablet is a monolayer tablet.
Dependencies are inferred from the claim text.